lineage histories specified to differentiate to a common cell type? What is the molecular basis for the reported VSMC origin-specific differences in response to TGFβ signaling 4, 5, 7 ? Do VSMCs exhibit origin-specific differences in their responses to inflammatory cytokines, oxidized lipids, extracellular matrix proteases or other stimuli related to vessel wall disease? Until now, the ability to address these questions, particularly in human cells, has been limited by the unavailability of VSMC progenitor subtypes and of well-characterized originspecific VSMC cell lines.
To generate lineage-specific VSMC subtypes in chemically defined media, Sinha and colleagues 2 exposed either human embryonic stem cells or induced pluripotent stem cells (collectively referred to as hPSCs) to a defined mixture of FGF2 (20 ng/ml), LY294002 (a PI3K inhibitor; 10 µM) and BMP4 (10 ng/ml), according to a previously described protocol for mesoderm differentiation from human embryonic stem cells 16 (Fig. 1) . From there, guided by studies describing a natural gradient of BMP signaling along the anterior-posterior axis of the primitive streak 17 , the authors manipulated BMP4 and LY294002 concentrations and found that treatment for 5 days with FGF2 (20 ng/ml, F20) and BMP4 (50 ng/ml) optimally generated cells expressing lateral plate mesoderm markers, whereas F20 plus LY294002 (10 µM) in the absence of BMP4 was optimal for producing cells that expressed paraxial mesoderm markers. Progenitor cells selectively expressing neuroectoderm markers were prepared according to a previously reported protocol employing FGF2 (12 ng/ml) and the activin-nodal inhibitor SB431542 (10 µM) 18 .
Sinha and colleagues 2 went on to direct their neuroectoderm, paraxial mesoderm and lateral plate mesoderm progenitors to a smooth muscle fate using a combination of PDGF-BB (10 ng/ml) and TGFβ1 (2 ng/ml) for 12 days. The resultant differentiated cells were then between VSMCs of different origins within a given artery wall are often very abrupt, with little or no intermixing [8] [9] [10] [11] . Moreover, lineagespecific differences in growth and in transcriptional responses to transforming growth factor-β (TGFβ) have been reported for VSMCs in vitro 4, 5 and in vivo 7 .
These observations from basic studies of vascular development support the notion that VSMC lineage diversity may contribute to sitespecific patterns of vascular disease in adults. They also suggest that optimal cell replacement therapies-for example, using bioengineered vascular grafts-should attempt to match the appropriate origin-specific VSMC subtype to the particular vascular segment undergoing treatment. This principle may also be extended to stem cell-based repair protocols for vascular smooth muscle and to cell therapies for other types of specialized smooth muscle tissue (e.g., airway, enteric, ciliary and urogenital). A better understanding of the intrinsic differences between different VSMC subtypes could even form the basis for novel approaches to disease management that involve replacing highly disease-susceptible VSMCs with disease-resistant VSMCs. For example, experiments in which atherosclerosissusceptible segments of abdominal aorta were transplanted to atherosclerosis-resistant positions in the thoracic aorta, and vice versa, revealed that aortic disease maps to segments with an intrinsic predisposition to acquire or resist disease rather than to their anatomic position per se 12 . Indeed, a role for VSMC lineage diversity has now been suggested in the pathogenesis of aortic aneurysms 13 , vascular calcification 14 and medial dissection 15 .
The growing recognition of the importance of VSMC lineage diversity in the nonuniform distribution of artery-wall diseases raises a number of fundamental questions about its molecular-genetic basis. How are VSMC progenitors of such diverse embryonic origins and Diseases of the blood vessel wall occur at specific sites in the vascular system even though most identified risk factors, such as hypercholesterolemia, hypertension and diabetes, are systemic 1 . A report in this issue promises to greatly facilitate research on the sitespecific origins of vascular disease. Sinha and colleagues 2 describe an in vitro strategy for generating large numbers of lineage-specific vascular smooth muscle cells (VSMCs) from human pluripotent stem cells (hPSCs) using a chemically defined protocol. Their approach offers a solution to the difficulty of obtaining VSMC subtype progenitors from early embryos in sufficient quantities for study.
In the search for an explanation of the anatomic specificity of vascular diseases, some investigators have turned to the developmental pathways by which blood vessels are formed in embryos. One intriguing clue resulting from these experiments is the surprising finding that VSMCs arise from multiple independent origins in development (reviewed by one of us in ref.
3). VSMCs originating from different types of embryonic progenitor show lineagespecific differences in growth, gene expression and functional properties [4] [5] [6] [7] . Mouse studies using lineage-restricted cre-recombinase alleles, together with classic grafting and ablation experiments in avian embryos, have shown that vascular smooth muscle is a highly mosaic tissue arising from at least eight unique origins in higher vertebrates 3 . The boundaries
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A method for differentiating human pluripotent stem cells into several subtypes of smooth muscle cell should aid the study and treatment of vascular disease. n e W s a n d v i e W s npg carefully and extensively characterized for gene expression phenotypes and functional properties. Microarray studies provided evidence for differentiation to cells that expressed a broad panel of smooth muscle markers with little or no expression of neural, cardiac, endothelial, hematopoietic or skeletal myocyte markersall of which are possible fates from neuroectoderm, paraxial mesoderm and lateral plate mesoderm progenitors.
The smooth muscle cells (SMCs) derived from the three progenitor types also exhibited sustained Ca 2+ influx and prolonged tonic contractions in response to carbachol that are characteristic of physiological smooth muscle contraction. In addition, in Matrigel angiogenesis assays, the cells were recruited to a perivascular position closely associated with endothelial cells. Based on the relative expression of SMTN (smoothelin) isoforms (SMTN-A and SMTN-B), Sinha and colleagues 2 concluded that the SMCs most closely resembled vascular, rather than visceral, smooth muscle.
The evidence described thus far indicates that the protocols produce VSMCs, but it is not sufficient to establish the critical point that origin-specific VSMC subtypes have been made. The strength of the paper lies in the characterization studies done to establish that, in all likelihood, origin-specific VSMC subtypes were produced, and with surprisingly high fidelity. For example, it is well established that SMC differentiation requires a core complex of the DNA binding protein serum response factor (SRF) together with at least one member of the myocardin family of SRF-binding transcriptional coactivators 19 . Gene deletion studies in mice have shown that neural crestderived VSMCs have a unique requirement for myocardin-related transcription factor-B (Mrtf-B, also called Mkl2) that is not shared by VSMCs originating from paraxial or lateral plate mesoderm 20, 21 . Using short interfering RNAs to silence MRTF-B/MKL2, Sinha and colleagues 2 found that SMC differentiation in neuroectoderm cultures was inhibited whereas SMC differentiation in paraxial or lateral plate mesoderm cultures proceeded normally.
A second line of evidence that the SMCs are origin specific is based on previous reports that TGFβ1 stimulates cell proliferation of cultured primary neuroectodermal SMCs but inhibits the growth of paraxial mesodermal SMCs isolated from the same vessels and maintained under identical conditions 4 . Likewise, angiotensin II (Ang II) promotes hyperplasia of neuroectodermal SMCs and causes hypertrophic growth of paraxial mesodermal SMCs in the same arteries 6 . Consistent with these findings, Sinha and colleagues 2 showed that neuroectoderm-derived VSMCs exposed to TGFβ1 or Ang II increased in cell numbers over 3 days, whereas VSMCs derived from paraxial mesoderm or lateral plate mesoderm cultures did not.
Finally, in certain cases, growth factors stimulate their own production, a feed-forward process called autoinduction. Neural crest-derived VSMCs exhibit strong autoinduction responses when stimulated with TGFβ1, whereas mesoderm-derived VSMCs isolated from the same vessels and maintained under identical conditions do not display any detectable autoinduction response 4 . When Sinha and colleagues 2 tested their hPSC-derived VSMC cultures, they found that only neuroectoderm-derived VSMCs exhibited autoinduction responses to TGFβ1-highly reminiscent of the previous report using native origin-specific SMC subtypes 4 .
Taken together, the authors' results make for a strong case that the in vitro-generated embryonic lineage-specific VSMCs closely resemble their in vivo counterparts. They also suggest exciting possibilities for scalable production of these cells for use in detailed studies of the biology of VSMC development and for the generation of novel bioengineered vascular grafts and other stem cell-based therapies. We highlight here several directions for future research.
First, smooth muscle tissue is present in many different organ systems other than blood vessels (e.g., airway, visceral, urogenital, lymphatic), where it carries out highly specialized functions specific to that organ system. Additional work is needed, beyond characterizing SMTN isoforms, to define the identity of the SMC types produced with the authors' protocols, particularly with regard to the possible formation of a hybrid SMC with mixed identity. Given the large number of environmental cues that normally guide development and differentiation of SMCs in embryos, it would be surprising if a gradient of BMP4 turns out to have sufficient information to replace the embryo.
Second, differentiation of VSMC subtypes in developing embryos occurs around mid gestation and is followed by a prolonged matu ration period during which the functional phenotype is 'fine tuned' . Given the short time frame for differentiation reported by Sinha and colleagues 2 , it is possible that one or more maturation steps have yet to be modeled in vitro. These maturation steps may become important as protocols to optimize the use of origin-specific VSMCs for clinical applications are developed.
Third, the question of whether pericytes are an intermediate step in VSMC differentiation from progenitor cells or are the products of a separate differentiation pathway has not yet been resolved. The authors' finding that CSPG4-positive cells did not coexpress Myh11 suggests that yet another selective pathway for progenitor cell specification to a pericyte fate remains to be characterized.
Fourth, the fact that paraxial mesoderm VSMCs did not proliferate in response to any of 
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the growth-promoting stimuli tested raises the question of whether they were more fully differentiated than the neuroectoderm and lateral plate mesoderm VSMCs under the conditions used, or whether they were deficient in pathways required for growth factor-stimulated cell proliferation. Given the results of aortic homograft transplantation studies described above 12 , which suggest that certain types of VSMC may be resistant to atherogenesis, this may be an important question to resolve. In summary, expertise in hPSC biology combined here with exquisite knowledge of VSMC development has culminated in a method that will allow ready access to different types of human VSMCs from a single genetic origin. If applied to patient induced pluripotent stem cells or to human embryonic stem cells with disease mutations, this approach will undoubtedly open up unprecedented opportunities to study aspects of vascular disease. With the phenotypic subtleties of mesoderm derivatives from hPSCs beginning to match those described for the neural lineages 22 , the impact on understanding human vascular development and disease can now be eagerly awaited.
replicate a weakly immunogenic conserved epitope in a setting where it will elicit hightiter neutralizing antibodies.
Grafting a binding site onto a scaffold protein would involve reproducing its topology in such a way that key contacts with the target are preserved. The b12 epitope is located on the viral envelope glycoprotein gp120 and overlaps with the site where CD4 binds gp120. Its structure has been defined based on a crystal structure of b12 bound to a gp120 core 5 . Azoitei et al. 3 undertook a computational analysis of the b12 epitope to identify two segments on gp120 that contribute ~80% of the b12-gp120 binding energy: a 10-residue segment called the CD4 binding (CD4b) loop and a 5-residue segment called the outer domain exit (ODe) loop.
A suite of computational algorithms was developed to guide subsequent immunogen design steps. 'Multigraft Match' interrogated the Protein Data Bank for proteins bearing segments that aligned to the CD4b and ODe loops and were likely to accept grafts without substantial disruption of their backbone structures. 'Multigraft Design' guided insertion of the CD4b and ODe loops into the scaffolds. This first design phase resulted in the grafted scaffold 2bodx_03, derived from the endoglucanase E-2 of Thermomonospora fusca, which bound b12 weakly.
To improve the scaffold's affinity, Azoitei et al. 3 used random mutagenesis to produce libraries of yeast displaying variants of 2bodx_03 on the cell surface 6 and screened the libraries by affinity selection with b12. This yielded the variant 2bodx_R3, with a tenfold improved affinity for b12. In a separate approach, the authors made elegant use of computational analyses to pinpoint optimal sites of amino-acid variation on the epitope scaffold; this allowed the theoretical diversity of a library to be small enough to be fully represented in an experimental library. A first library of 2bodx_03 variants was built around optimal ODe loop connections and a subset of CD4b loop connections, and was screened with b12. The resulting affinity-enriched pool of 2bodx_03 variants was then used to generate a second library containing a more fully diversified set of CD4b loop connections. Screening led to 2bodx_42, with a >1,800-fold affinity improvement. Further engineering of 2bodx_42 to add the 2bodx_R3 mutations yielded the high-affinity 2bodx_43 (K D ≈ 33 nM). Binding studies with a panel of antibodies specific to the CD4 binding revealed that 2bodx_43 is specific for b12, and mutational analysis demonstrated dependence on residues within and outside of the grafted sites.
A comparison of the structure of the gp120-b12 complex 5 with that of the 2bodx_43-b12 epitopes have typically failed to generate effective immunogens 1, 2 . A recent study by Azoitei et al. 3 in Science reports notable progress in recapitulating a discontinous epitope on a protein scaffold. The authors use a combination of computational algorithms and combinatorial antigen libraries to graft onto a foreign protein scaffold the major features of the discontinuous epitope for b12, a monoclonal antibody that neutralizes a spectrum of HIV isolates 4 .
After infection by a rapidly mutating virus, antibody responses against the viral envelope glycoproteins tend to be directed against variable, strain-specific epitopes rather than against conserved epitopes shared by many viral variants. Similarly, immunogens derived from viral envelope glycoproteins usually elicit antibodies that neutralize only viral variants closely related to the immunogen. Protein engineering has the potential to A long-standing goal in the field of protein design is the ability to engineer a protein to display a functional facsimile of a natural protein binding site. Nowhere is this capability more sought after than in vaccine design, especially for vaccines against infection by highly mutable pathogens, such as HIV-1, influenza and hepatitis C viruses, which are best prevented by broadly neutralizing antibodies. Some success has been achieved in producing immunogenic mimics of epitopes composed of a single, continuous segment, but attempts to mimic discontinuous 
